Fig. 1
Expression of EGFL7 by human blood-brain barrier endothelial cells is altered in the CNS of MS subjects. a Expression of EGFL7 (red) by brain vessels (collagen IV, green) in human healthy control (Ctl, temporal), MS active lesion (AL, temporal), MS chronic inactive lesion (CI, temporal) and MS normal-appearing white matter (NAWM, frontal). Nuclei (DAPI) = blue. Representative of n = 5 MS patients and 5 Ctl. Scale bar = 10 μm. n ≥ 5 sections/subject were analyzed. b–d Semi-quantitative analysis of EGFL7 expression by BBB-ECs as presented in (a) according to (b) mean pixel intensity, (c) relative pixel intensity calculated as mean pixel intensity multiplied by area, and (d) area of positive signal for EGFL7 normalized to total vessel area (positive for collagen IV). e, f Expression of EGFL7 (red) in (e) areas of perivascular infiltration or (f) compared to healthy control tissue. CD31 expression (green), nuclei (blue). Scale bar = 50 μm. g Relative expression of EGFL7 mRNA by ex vivo human leukocytes sorted by CD4, CD8, CD14 or CD19 population, and in human BBB-ECs in primary culture. 1 dot = 1 donor. h Relative expression of EGFL7 mRNA by human BBB-ECs in primary culture in resting (Ctl), inflamed (TNF + IFN-γ 100 U/ml) or astrocyte-conditioned medium (ACM) conditions. n ≥ 8 different preps per condition. Statistical analysis performed by one-way ANOVA followed by Tukey’s multiple comparison test. *p < 0.05. All data presented as mean ± standard error of the mean (SEM)
